SciELO - Scientific Electronic Library Online

vol.80 issue6What's new in tuberculosis vaccines? author indexsubject indexarticles search
Home Page  

Services on Demand




Related links


Bulletin of the World Health Organization

Print version ISSN 0042-9686


PABLOS-MENDEZ, Ariel; GOWDA, Deepthiman K.  and  FRIEDEN, Thomas R.. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull World Health Organ [online]. 2002, vol.80, n.6, pp.489-495. ISSN 0042-9686.

The emergence and spread of multidrug-resistant tuberculosis (MDR-TB), i.e. involving resistance to at least isoniazid and rifampicin, could threaten the control of TB globally. Controversy has emerged about the best way of confronting MDR-TB in settings with very limited resources. In 1999, the World Health Organization (WHO) created a working group on DOTS-Plus, an initiative exploring the programmatic feasibility and cost-effectiveness of treating MDR-TB in low-income and middle-income countries, in order to consider the management of MDR-TB under programme conditions. The challenges of implementation have proved more daunting than those of access to second-line drugs, the prices of which are dropping. Using data from the WHO/International Union Against Tuberculosis and Lung Disease surveillance project, we have grouped countries according to the proportion of TB patients completing treatment successfully and the level of MDR-TB among previously untreated patients. The resulting matrix provides a reasonable framework for deciding whether to use second-line drugs in a national programme. Countries in which the treatment success rate, i.e. the proportion of new patients who complete the scheduled treatment, irrespective of whether bacteriological cure is documented, is below 70% should give the highest priority to introducing or improving DOTS, the five-point TB control strategy recommended by WHO and the International Union Against Tuberculosis and Lung Disease. A poorly functioning programme can create MDR-TB much faster than it can be treated, even if unlimited resources are available. There is no single prescription for controlling MDR-TB but the various tools available should be applied wisely. Firstly, good DOTS and infection control; then appropriate use of second-line drug treatment. The interval between the two depends on the local context and resources. As funds are allocated to treat MDR-TB, human and financial resources should be increased to expand DOTS worldwide.

Keywords : Tuberculosis, Multidrug-resistant [drug therapy]; Tuberculosis, Multidrug-resistant [epidemiology]; Tuberculosis, Multidrug-resistant [history]; Antitubercular agents [therapeutic use]; Antitubercular agents [economics]; Treatment outcome; Developing countries.

        · abstract in French | Spanish     · text in English     · English ( pdf )